Sofosbuvir based therapy in Hepatitis C patients with and without cirrhosis: Is there difference? - Concepedia

Concepedia

Publication | Open Access

Sofosbuvir based therapy in Hepatitis C patients with and without cirrhosis: Is there difference?

DOI Full Paper Access

20

Citations

19

References

2017

Year

Md Shahid Sarwar, Anwaar A Khan

Pakistan Journal of Medical Sciences

Abstract

Treatment outcome with sofosbuvir/ribavirin combination therapy in cirrhosis patients is suboptimal especially in those with decompensation as compared to patients without liver cirrhosis.

References

	Year	Citations
Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Chander Shekhar, Monaghan Pj, Jane Morris, IRIS Research product catalog (Sapienza University of Rome) Food IntoleranceFunctional Gastrointestinal DisorderSimilar DisordersPsychiatryGastrointestinal Pharmacology	2013	2.7K
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Ira M. Jacobson, Stuart C. Gordon, Kris V. Kowdley, New England Journal of Medicine	2013	1.1K
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 Stefan Zeuzem, Geoffrey Dusheiko, Riina Salupere, New England Journal of Medicine	2014	796
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis Graham R. Foster, William L. Irving, Michelle Cheung, Journal of Hepatology HepatologyHepatitis CViral HepatitisLiver PhysiologyImmunology	2016	490
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis Michelle Cheung, Alex J Walker, Ben Hudson, Journal of Hepatology HepatologyHepatitis CViral HepatitisLiver PhysiologyAntiviral Therapy	2016	402
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection Graham R. Foster, Stephen Pianko, Ashley Brown, Gastroenterology HepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitis	2015	249
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort Tania M. Welzel, Jörg Petersen, Kerstin Herzer, Gut	2016	196
Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis Eric Lawitz, Fred Poordad, Diana M. Brainard, Hepatology	2014	125
Improvement of liver function parameters in advanced <scp>HCV</scp> ‐associated liver cirrhosis by <scp>IFN</scp> ‐free antiviral therapies Katja Deterding, Christoph Höner zu Siederdissen, Kerstin Port, Alimentary Pharmacology & Therapeutics	2015	120
The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life Zobair M. Younossi, Maria Stepanova, Fatema Nader, Alimentary Pharmacology & Therapeutics	2015	96

Page 1